246 Infos zu Günter Fingerle-rowson
Mehr erfahren über Günter Fingerle-rowson
Infos zu
- Tubulis
- Chief Medical Officer
- Zitiert
- University
- Macrophage
- Richard Bucala
- Roche
- MIF
- Obinutuzumab
- Officer at Tubulis
- Michael
16 Aktuelle Nachrichten
GoingPublic.devor 1 Tag — ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer von Tubulis. Der von der FDA gewährte Fast-Track-Status soll die Entwicklung ...
Tubulis appoints Günter Fingerle-Rowson as Chief Medical ...The Globe and Mail— Tubulis today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the leadership team and — Tubulis today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the leadership team and ...
Tubulis appoints Günter Fingerle-Rowson as Chief Medical Officer...MUNICH, GERMANY, April 20, 2021– Tubulis, today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the leadership team and to further build the company’s clinical expertise. Dr. Fingerle-Rowson is an experienced
Milliarden-Boost für Tubulis durch Bristol Myers SquibbGoingPublic.de— “ Das Tubulis-Management-Team v.l.n.r.: CMO Dr. Günter Fingerle-Rowson, MD, CSO Dr. Jonas Helma-Smets, CEO Dr. Dominik Schumacher, CBO Dr — “ Das Tubulis-Management-Team v.l.n.r.: CMO Dr. Günter Fingerle-Rowson, MD, CSO Dr. Jonas Helma-Smets, CEO Dr. Dominik Schumacher, CBO Dr ...
9 Profile in Sozialen Netzwerken
LinkedIn: Günter Fingerle-Rowson – Chief Medical OfficerLinkedInGünter Fingerle-Rowson · Chief Medical Officer at Tubulis GmbH · Melden · Melden · Info · Aktivitäten · Berufserfahrung · Ausbildung · Weitere Aktivitäten von Günter ...
LinkedIn: Günter Fingerle-Rowson - technology #adc #cd30 - LinkedInmy.linkedin.com › posts › günter-fingerle-rowsonPaparan Günter Fingerle-Rowson. Lihat profil Günter Fingerle-Rowson · Günter Fingerle-Rowson. Chief Medical Officer at Tubulis GmbH.
LinkedIn: Günter Fingerle-Rowson's Post - technology #adc #cd30linkedin.comGünter Fingerle-Rowson's Post. View profile for Günter Fingerle-Rowson · Günter Fingerle-Rowson. Chief Medical Officer at Tubulis GmbH.
Twitter Profil: Tubulis (@Tubulis_GmbH) / Xtwitter.comDon't miss our CMO, Günter Fingerle-Rowson. @EORTC. 's CLTG meeting where he will present new data on our #lymphoma-targeting #ADC candidate TUB-010, based on ...
8 Hobbys & Interessen
Original Article Obinutuzumab for the First-Line Treatment ...The New England Journal of MedicineB., Marek Trněný, M.D., Michael Wenger, M.D., Günter Fingerle-Rowson, M.D., Ph.D., Kaspar Rufibach, Ph.D., Tom Moore, M.B., Ch.B., Michael Herold, M.D., and ... B., Marek Trněný, M.D., Michael Wenger, M.D., Günter Fingerle-Rowson, M.D., Ph.D., Kaspar Rufibach, Ph.D., Tom Moore, M.B., Ch.B., Michael Herold, M.D., and ...
Obinutuzumab plus bendamustine versus ...The Lancet... Günter Fingerle-Rowson, MD, Prof Bruce D Cheson, MD. The Lancet Oncology. Volume 17 Issue 8 Pages (August 2016). DOI: S (16) Günter Fingerle-Rowson, MD, Prof Bruce D Cheson, MD. The Lancet Oncology. Volume 17 Issue 8 Pages (August 2016). DOI: S (16)
Tubulis appoints Günter Fingerle-Rowson as Chief Medical Officer...20. Apr · Tubulis today announced the appointment of Günter Fingerle-Rowson, MD, PhD, as Chief Medical Officer to complement the leadership team and to further.
Obinutuzumab plus bendamustine versus ...EM consulte... Günter Fingerle-Rowson, MD, Bruce D Cheson, ProfMD. a British Columbia Cancer Agency, Vancouver, BC, Canada. b University of British Columbia, Vancouver Günter Fingerle-Rowson, MD, Bruce D Cheson, ProfMD. a British Columbia Cancer Agency, Vancouver, BC, Canada. b University of British Columbia, Vancouver ...
3 Business-Profile
Xing: Günter Fingerle-Rowson - Medical Director - Hoffmann LaRocheGünter Fingerle-Rowson, Basel Berufserfahrung, Kontaktdaten, Portfolio und weitere Infos: Erfahr mehr – oder kontaktier Günter Fingerle-Rowson direkt bei XING.
Günter FINGERLE-ROWSON | Doctor of Medicine | Research profileGünter Fingerle-Rowson CD74 is a surface protein expressed on immune cells, which acts as receptor for the chemokine macrophage migration inhibitory factor (MIF).
Günter KRAUSE | Group Leader | Dr. rer. nat.ResearchGateGünter Fingerle-Rowson. Unlabelled: Survival of chronic lymphocytic leukemia (CLL) cells depends on stimuli provided by a suitable ... Günter Fingerle-Rowson. Unlabelled: Survival of chronic lymphocytic leukemia (CLL) cells depends on stimuli provided by a suitable ...
1 Firmen-Mitarbeiter
Dr. Günter Fingerle-Rowson, MDTubulisAbout us · Team · Supervisory Board · Scientific Advisory Board · Technology · Pipeline · Investors · Career · News & Events · Contact us. About us · Team · Supervisory Board · Scientific Advisory Board · Technology · Pipeline · Investors · Career · News & Events · Contact us.
2 Persönliche Webseiten
Günter Fingerle-Rowson Email & Phone Number | MorphoSys AGContactOutTo contact Günter Fingerle-Rowson send an email to or .
15 Bücher zum Namen
Macrophage Migration Inhibitory Factor Coordinates DNA ...Taylor & Francis Onlinevon A Nemajerova · · Zitiert von: 51 — ,. Ute M. Moll. ,. Oleksi Petrenko. &. Günter Fingerle-Rowson. Pages | Published online: 01 May Cite this article · https://doi.org cc. von A Nemajerova · · Zitiert von: 51 — ,. Ute M. Moll. ,. Oleksi Petrenko. &. Günter Fingerle-Rowson. Pages | Published online: 01 May Cite this article · https://doi.org cc.
Randomized phase II trial comparing obinutuzumab (GA101) with ...biblio.ugent.be... Günter Fingerle-Rowson, and Oliver W Press “Randomized Phase II Trial Comparing Obinutuzumab (GA101) with Rituximab in Patients with Relapsed CD20+ ...
Günter Fingerle-Rowson | Hoffmann-La Roche | 70 PublicationsAI Chat for scientific PDFs | SciSpaceGünter Fingerle-Rowson is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Obinutuzumab & Follicular ...
Successful Drug Discovery, Volume 3google.lv... Günter Fingerle-Rowson, and Pablo Umaña Introduction 245 Preclinical Experience with Obinutuzumab 246 Characteristics and Mechanisms of Action of Type I and ...
33 Dokumente
American Journal of Hematology | Blood Research JournalWiley Online Libraryvon O Al‐Sawaf · · Zitiert von: 7 — ... Günter Fingerle-Rowson,. Günter Fingerle-Rowson. F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers by this author · Stephan ... von O Al‐Sawaf · · Zitiert von: 7 — ... Günter Fingerle-Rowson,. Günter Fingerle-Rowson. F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers by this author · Stephan ...
Tubulis appoints Günter Fingerle-Rowson as Chief Medical ...Coparion— Tubulis appoints Günter Fingerle-Rowson as Chief Medical Officer to lead the clinical development of its new generation of ADCs. MUNICH ...
Discovery and Development of Obinutuzumab (GAZYVA ...Wiley Online Libraryvon C Klein · · Zitiert von: 1 — Günter Fingerle-Rowson,. Günter Fingerle-Rowson. Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers ... von C Klein · · Zitiert von: 1 — Günter Fingerle-Rowson,. Günter Fingerle-Rowson. Pharma Development Oncology, F. Hoffmann-La Roche, Basel, Switzerland. Search for more papers ...
Delayed development of chronic lymphocytic leukemia in the ...ashpublications.orgvon N Reinart · · Zitiert von: 115 — Günter Fingerle-Rowson. Günter Fingerle-Rowson. 1Department I of Internal Medicine, University Hospital Cologne, and Center for Integrated Oncology Köln-Bonn ... von N Reinart · · Zitiert von: 115 — Günter Fingerle-Rowson. Günter Fingerle-Rowson. 1Department I of Internal Medicine, University Hospital Cologne, and Center for Integrated Oncology Köln-Bonn ...
15 Wissenschaftliche Publikationen
Privatdozent Dr. Günter Fingerle-Rowson - DFG - GEPRISDFG - GEPRISPrivatdozent Dr. Günter Fingerle-Rowson, Klinik für Innere Medizin IKöln. Privatdozent Dr. Günter Fingerle-Rowson, Klinik für Innere Medizin IKöln.
MIF coordinates the cell cycle with DNA damage checkpoints ...BioMed Centralvon G Fingerle-Rowson · · Zitiert von: 48 — MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Günter Fingerle-Rowson &; Oleksi Petrenko. Cell ... von G Fingerle-Rowson · · Zitiert von: 48 — MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Günter Fingerle-Rowson &; Oleksi Petrenko. Cell ...
Prognostic impact of somatic mutations in diffuse large B- ...Archive ouverte HALvon CR Bolen · · Zitiert von: 48 — ... Günter Fingerle-Rowson (3) , Tina Nielsen (3) , Georg Lenz (8) , Mikkel Z. Oestergaard (3). Afficher plus de détails. 1 Genentech, Inc. [San Francisco] von CR Bolen · · Zitiert von: 48 — ... Günter Fingerle-Rowson (3) , Tina Nielsen (3) , Georg Lenz (8) , Mikkel Z. Oestergaard (3). Afficher plus de détails. 1 Genentech, Inc. [San Francisco]
Evaluation of the International Prognostic Index for Chronic ...ScienceDirect.comvon V Goede · · Zitiert von: 11 — ... Guenter Fingerle-Rowson, MD PhD,5 Stephan Stilgenbauer, MD,6 Manuela A. Bergmann, MD,7 Barbara F. Eichhorst, MD,8 Michael Hallek8,9 1Department I of ... von V Goede · · Zitiert von: 11 — ... Guenter Fingerle-Rowson, MD PhD,5 Stephan Stilgenbauer, MD,6 Manuela A. Bergmann, MD,7 Barbara F. Eichhorst, MD,8 Michael Hallek8,9 1Department I of ...
8 Allgemeine Veröffentlichungen
A Review of Obinutuzumab (GA101), a Novel Type II Anti- ...Springervon K Tobinai · · Zitiert von: 174 — Günter Fingerle-Rowson is an employee at F. Hoffmann-La Roche Ltd. and owns stock in F. Hoffmann-La Roche Ltd. Compliance with Ethics ... von K Tobinai · · Zitiert von: 174 — Günter Fingerle-Rowson is an employee at F. Hoffmann-La Roche Ltd. and owns stock in F. Hoffmann-La Roche Ltd. Compliance with Ethics ...
Changes in the Diagnosis and Treatment of Low Grade ...ResearchGateGünter Fingerle-Rowson. The cost-effectiveness of rituximab in combination with fludarabine/cyclophosphamide (R-FC) for the first line ... Günter Fingerle-Rowson. The cost-effectiveness of rituximab in combination with fludarabine/cyclophosphamide (R-FC) for the first line ...
Expansion of CD14+CD16+Monocytes in Critically Ill ...Springervon G Fingerle-Rowson · · Zitiert von: 110 — Authors and Affiliations. Department of Internal Medicine I, Klinikum Grosshadern, University of Muenchen, Muenchen, FRG. Günter Fingerle-Rowson & Jens Auers. von G Fingerle-Rowson · · Zitiert von: 110 — Authors and Affiliations. Department of Internal Medicine I, Klinikum Grosshadern, University of Muenchen, Muenchen, FRG. Günter Fingerle-Rowson & Jens Auers.
MINIMAL RESIDUAL DISEASE AND OUTCOMES IN ...ResearchGate— Günter Fingerle-Rowson. Introduction: Obinutuzumab is a novel humanized type II glycoengineered anti-CD20 antibody — Günter Fingerle-Rowson. Introduction: Obinutuzumab is a novel humanized type II glycoengineered anti-CD20 antibody ...
3 Video- & Audioinhalte
Tubulis schließt strategische Partnerschaft mit BMSInnovations- und Gründerzentrum Biotechnologie IZB— Günter Fingerle-Rowson, MD, CMO; Dr. Jonas Helma-Smets, CSO; Dr. Dominik Schumacher, CEO; Dr. Ingo Lehrke, CBO; Dr. Björn Hock, CDO ...
m4 Award Gewinner Tubulis: erster Patient in Phase I/IIa ...bio-m.org— Günter Fingerle-Rowson, Chief Medical Officer bei Tubulis. "Die neuartige P5-Technologie, die wir in TUB-040 verwenden, verbessert die — Günter Fingerle-Rowson, Chief Medical Officer bei Tubulis. "Die neuartige P5-Technologie, die wir in TUB-040 verwenden, verbessert die ...
m4 Award Gewinner Tubulis auf Erfolgsspur: bio-m.org— Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Member of the Supervisory Board), Dr. Ingo — Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Member of the Supervisory Board), Dr. Ingo ...
5 Meinungen & Artikel
1stOncology— ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer at Tubulis. "The novel P5 technology we use in TUB-040 improves upon current ...
First Patient Dosed in Tubulis Phase I/IIa ADC Trial for TUB ...Patsnap Synapsevor 3 Tagen — ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer at Tubulis. “Initiating our first clinical trial represents an important milestone ... vor 3 Tagen — ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer at Tubulis. “Initiating our first clinical trial represents an important milestone ...
128 Mio. EUR Runde für Münchner Biotech-Start-up TubulisVC Magazin— Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Mitglied des Aufsichtsrates), Dr. Ingo Lehrke (CBO) — Günter Fingerle-Rowson, MD (CMO), Dr. Jonas Helma-Smets (CSO), Dr. Dominik Schumacher (CEO, Mitglied des Aufsichtsrates), Dr. Ingo Lehrke (CBO) ...
MRD response in relapsed/refractory FL after ...Nature Journalvon C Pott · · Zitiert von: 19 — Nathalie Spielewoy, Guenter Fingerle-Rowson, Kirsten Mundt & Elisabeth Wassner-Fritsch. Roche, Welwyn Garden City, UK. Chris Harbron.
125 Webfunde aus dem Netz
Tubulis Receives FDA Fast Track Designation for Antibody ...Yahoo Financevor 2 Tagen — ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer of Tubulis. "The FDA decision brings us one step closer to our goal of delivering the ... vor 2 Tagen — ... Günter Fingerle-Rowson, MD, PhD, Chief Medical Officer of Tubulis. "The FDA decision brings us one step closer to our goal of delivering the ...
Guenter Fingerle-RowsonLinkos.czGuenter Fingerle-Rowson. Pharma Development, F. Hoffmann-La Roche Ltd. ( Basel, Switzerland). Odborné práce publikované na Linkos.cz. Přehled odborných textů ... Guenter Fingerle-Rowson. Pharma Development, F. Hoffmann-La Roche Ltd. ( Basel, Switzerland). Odborné práce publikované na Linkos.cz. Přehled odborných textů ...
martin Krause - Englisch-Deutsch ÜbersetzungPONSThe groups of Associate Professor Günter Fingerle-Rowson and Dr Marco Herling work on the identification of new oncogenic signal transduction pathways in CLL ...
Günter Fingerle-Rowson - CMO at TubulisThe OrgGünter Fingerle-Rowson is the current CMO at Tubulis. Günter has also previously worked as an Associate Group Medical Director, Global Development Team ...
Günter Fingerle-Rowson (fingerlerowson) - ProfilePinterest - DeutschlandSee what Günter Fingerle-Rowson (fingerlerowson) has discovered on Pinterest, the world's biggest collection of ideas. See what Günter Fingerle-Rowson (fingerlerowson) has discovered on Pinterest, the world's biggest collection of ideas.
Günter Fingerle-Rowson (fingerlerowson) - Profile | PinterestPinterest - ピンタレストGünter Fingerle-Rowson. fingerlerowson. ·. フォロワー:0 人. ·. フォロー中:0 人. フォロー. fingerlerowson さんはまだピンを保存していません.
Günter Fingerle-Rowson | CiNii Research - 国立情報学研究所CiNiiGünter Fingerle-Rowson · この人物について · 関連論文 · 関連研究データ · 関連図書・雑誌 · 関連博士論文 · 関連プロジェクト · 関連その他成果物 · 詳細情報.
Guenter Fingerle-RowsonORCIDGuenter Fingerle-Rowson · · Personal information · Activities. Guenter Fingerle-Rowson · · Personal information · Activities.
"MRD response in relapsed/refractory FL after ...Digital Commons@Beckervon C Pott · · Zitiert von: 30 — ... Guenter Fingerle-Rowson, F. Hoffmann-La Roche Ltd · Chris Harbron, Roche · Kirsten Mundt, F. Hoffmann-La Roche Ltd · Elisabeth Wassner-Fritsch, ... von C Pott · · Zitiert von: 30 — ... Guenter Fingerle-Rowson, F. Hoffmann-La Roche Ltd · Chris Harbron, Roche · Kirsten Mundt, F. Hoffmann-La Roche Ltd · Elisabeth Wassner-Fritsch, ...
BioTech-Innovation im Kampf gegen Krebs: 128 Millionen ...Gründerland Bayern... Günter Fingerle-Rowson, Dr. Jonas Helma-Smets, Dr. Dominik Schumacher, Dr. Ingo Lehrke und Dr. Björn Hock. © Tubulis März 24. BioTech-Innovation im Günter Fingerle-Rowson, Dr. Jonas Helma-Smets, Dr. Dominik Schumacher, Dr. Ingo Lehrke und Dr. Björn Hock. © Tubulis März 24. BioTech-Innovation im ...
A model for predicting effect of treatment on progression-free ...ashpublications.orgGünter Fingerle-Rowson,. Günter Fingerle-Rowson. 2F. Hoffmann-La Roche Ltd, Basel, Switzerland;. Search for other works by this author on: This Site · PubMed.
FDA Approves Tepylute in Breast and Ovarian CancerTargeted Oncologyvor 17 Stunden — ... Günter Fingerle-Rowson, MD, PhD, chief medical officer of Tubulis, in a press release. "The FDA decision brings us one step closer to our ... vor 17 Stunden — ... Günter Fingerle-Rowson, MD, PhD, chief medical officer of Tubulis, in a press release. "The FDA decision brings us one step closer to our ...
FDA Fast Track for TUB-040: ADC Shows Promise ...Targeted Oncologyvor 1 Tag — ... Günter Fingerle-Rowson, MD, PhD, chief medical officer of Tubulis, in a press release. "The FDA decision brings us one step closer to our ... vor 1 Tag — ... Günter Fingerle-Rowson, MD, PhD, chief medical officer of Tubulis, in a press release. "The FDA decision brings us one step closer to our ...
HarvardHaematologicaPaulson, Eugene Kim, Umberto Vitolo, Alice Di Rocco, Günter Fingerle-Rowson, Tina Nielsen, Georg Lenz and Mikkel Z. Oestergaard (2019) “Prognostic impact of ... Paulson, Eugene Kim, Umberto Vitolo, Alice Di Rocco, Günter Fingerle-Rowson, Tina Nielsen, Georg Lenz and Mikkel Z. Oestergaard (2019) “Prognostic impact of ...
FDG-PET is prognostic and predictive for progression-free ...Ateneo - UPO... Guenter Fingerle-Rowson, Claude Berge, Deniz Sahin, Oliver Press, Laurie Sehn. Department of Translational Medicine. Research output: Contribution to journal Guenter Fingerle-Rowson, Claude Berge, Deniz Sahin, Oliver Press, Laurie Sehn. Department of Translational Medicine. Research output: Contribution to journal ...
Influence of Chemotherapy on Efficacy and SafetyResearch Explorer The University of Manchestervon W Hiddemann · · Zitiert von: 220 — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ... von W Hiddemann · · Zitiert von: 220 — ... Günter Fingerle-rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus. Division of Cancer Sciences (L5). Research output: Contribution to journal › Article ...
Forsthuber, Thomas G., M.D., Ph.D. - MicrobiologyUT Health San AntonioNiannian Ji, Andra Kovalovsky, Günter Fingerle-Rowson, M. Neal Guentzel, and Thomas G. Forsthuber. Macrophage migration inhibitory factor promotes ... Niannian Ji, Andra Kovalovsky, Günter Fingerle-Rowson, M. Neal Guentzel, and Thomas G. Forsthuber. Macrophage migration inhibitory factor promotes ...
FDG-PET is prognostic and predictive for progression-free survival in ...research.uniupo.it... Guenter Fingerle-Rowson, Claude Berge, Deniz Sahin, Oliver Press, Laurie Sehn. Department of Translational Medicine. Research output: Contribution to journal ...
Immunochemotherapy With Obinutuzumab or Rituximab for ...ascopubs.orgGünter Fingerle-Rowson. Employment: Roche. Stock or Other Ownership: Roche. Marcel Wolbers. Employment: Roche. Consulting or Advisory Role: Roche. Tina Nielsen.
MRD response in relapsed/refractory FL after ...Washington University in St. Louis... Guenter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Elisabeth Wassner-Fritsch, Bruce D. Cheson. Section of Medical Oncology · Siteman Cancer Center. Research Guenter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Elisabeth Wassner-Fritsch, Bruce D. Cheson. Section of Medical Oncology · Siteman Cancer Center. Research ...
Bedeutung zum Vornamen Günter
Männlicher Vorname (Deutsch): Günter; Althochdeutsch (Zweigliedriger Name); gund = der Kampf; heri = das Heer, der Krieger; alter deutscher zweigliedriger Name; im Nibelungenlied war 'Gunther' der Burgunderkönig
Verwandte Personensuchen
- Clemens-Martin Wendtner
- Marcel Wolbers
- Georg Lenz
- Jörg Klug
- Philipp Lacher
- Andreas Meinhardt
- Kirsten Fischer
- Suada Fröhlich
- Ursula Fingerle
- Ralf Henkeler
- Rolf Abel
Personensuche zu Günter Fingerle-rowson & mehr
Die Personensuchmaschine Namenfinden.de ist die neue Personensuche für Deutschland, die Profile, Kontaktdaten, Bilder, Dokumente und Webseiten zu Günter Fingerle-rowson und vielen weiteren Namen aus öffentlich zugänglichen Quellen im Internet anzeigt.